SINE compounds activate exportin 1 degradation through an allosteric mechanism
- PMID: 41286136
- DOI: 10.1038/s41589-025-02058-0
SINE compounds activate exportin 1 degradation through an allosteric mechanism
Abstract
Overexpression of exportin 1 (XPO1/CRM1) in cancer cells mislocalizes numerous cancer-related nuclear export cargoes. Covalent selective inhibitors of nuclear export (SINEs), including the cancer drug selinexor, restore proper nuclear localization by blocking XPO1-cargo interaction. These inhibitors also induce XPO1 degradation through the Cullin-RING E3 ligase (CRL) substrate receptor ASB8. Here we present cryo-electron microscopy structures revealing ASB8 binding to a cryptic XPO1 site that is exposed upon SINE conjugation. Unlike typical molecular glue degraders that directly bridge CRLs and substrates, SINEs bind XPO1 independently of ASB8, triggering an allosteric mechanism that enables high-affinity ASB8 recruitment, leading to XPO1 ubiquitination and degradation. ASB8-mediated degradation is also triggered by the endogenous itaconate derivative 4-octyl itaconate, suggesting that synthetic XPO1 inhibitors exploit a native cellular mechanism. This allosteric XPO1 degradation mechanism expands known modes of targeted protein degradation beyond molecular glue degraders and proteolysis-targeting chimeras of CRL4.
© 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.
Conflict of interest statement
Competing interests: Y.M.C. was a consultant to and holds equity options in Karyopharm Therapeutics. Y.M.C. is also a consultant to Telo Therapeutics. B.K., M.J., B.P. and D.D. are employees of KU Leuven, which has a license agreement on KPT-SINE–XPO1 inhibitors. Y.L. was an employee of Karyopharm Therapeutics and still retains ownership of company shares. S.S. is a former employee of Karyopharm Therapeutics, holds patents (8999996, 9079865, 9714226, PCT/US12/048319 and I574957) on hydrazide-containing nuclear transport modulators and uses and holds pending patents (PCT/US12/048319, 499/2012, PI20102724 and 2012000928) on hydrazide-containing nuclear transport modulators and uses. The other authors declare no competing interests.
References
MeSH terms
Substances
Grants and funding
- R35GM144137/U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)
- T32GM131963/U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS)
- I-1532/Welch Foundation
- RP150053/Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas)
- RP170170/Cancer Prevention and Research Institute of Texas (Cancer Prevention Research Institute of Texas)
LinkOut - more resources
Full Text Sources
